Inx-09114

Inx-09114

SCHEMBL14946248

C[C@]1(O)[C@@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O[C@H]1n1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY2 P41231 2/20 0.60
P2RY4 P51582 2/20 0.60
TGM2 P21980 1/20 0.58
POLB P06746 1/20 0.57
FUT5 Q11128 1/20 0.56
KRAS P01116 2/20 0.55
P2RY6 Q15077 2/20 0.54
NT5E P21589 1/20 0.53
POLG P54098 1/20 0.52
PNP P00491 1/20 0.51
DCPS Q96C86 1/20 0.49
P2RX3 P56373 3/20 0.49
ENPP1 P22413 2/20 0.49
P2RY1 P47900 2/20 0.49
P2RX1 P51575 2/20 0.49
P2RX4 Q99571 2/20 0.49
P2RY11 Q96G91 1/20 0.49
P2RY12 Q9H244 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Inx-09114 SCHEMBL10819844 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL21006183 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL13522450 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL14853807 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL14929056 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL23319265 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL720114 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
Inx-09114 SCHEMBL21007234 1.00 P2RY2 (0.60) P2RY2P2RY4TGM2POLBFUT5
SCHEMBL13522449 0.99 TGM2 (0.59) P2RY2P2RY4TGM2POLBFUT5
SCHEMBL1576874 0.99 TGM2 (0.59) P2RY2P2RY4TGM2POLBFUT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 P2RY2 558/4885P2RY4 427/4885TGM2 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.